{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Teprotumumab, a Human Monoclonal Antibody Insulin-like Growth Factor-1 Receptor Inhibitor for Thyroid Eye Disease

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Select common characteristics related to thyroid eye disease (TED).
  2. Apply treatment strategies for a patient with TED.

Learning Outcomes

Seventy-five percent of participants will demonstrate competency in clinical reasoning regarding the management of a patient with thyroid eye disease by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $21.95

Credits:

  • ANCC 2.0 CH / 1.0 APH
  • DC - BON 2.0 CEH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH
  • NM - BON 2.0 CH
  • SC - BON 2.0 CH
  • WV - BOERN 2.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Awarded Advanced Pharmacology Hours













Test Code: CNS0522
Published: May/Jun 2022
Expires: 3/7/2025
Required Passing Score: 7/10 (70%)
Authors: Patricia Anne O'Malley, PhD, APRN-CNS